乙型肝炎治疗研究进展

Research Progress of Hepatitis B Treatment

乙性肝炎病毒感染所导致的慢性肝炎是我国的一个大问题,给患者及社会带来了很大负担。慢性乙型肝炎现行治疗主要依靠干扰素、核苷类似物等,其存在高耐药、低耐受以及不良反应等问题。新的、更为安全有效的治疗药物及方法亟待发展。最近,科学家们发现人体内的TRIM22分子对抑制乙肝病毒的复制起到重要作用,为乙肝的治疗及有效药物的研发开辟了新的道路。

Chronic hepatitis caused by hepatits B virus infection pose a majoy problem in China and incur substantial burden to patients and society.Current treatments for Hepatitis B mostly relies on interferon,nucleoside and so on.Because of the high rate of resistance,poor tolerability and possible adverse reaction,the new,safe and more effective drugs and treatments are urgently needed.Recently,researchers found that the TRIM22 molecules in human body play an important role on restraining duplicate of HBV,and gave a new way to treatments of Hepatitis B and invention of effective drugs.